Jane Street Group LLC Acquires 17,205 Shares of Zymeworks Inc. (NYSE:ZYME)

Jane Street Group LLC raised its holdings in Zymeworks Inc. (NYSE:ZYME) by 27.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,326 shares of the company’s stock after buying an additional 17,205 shares during the period. Jane Street Group LLC owned about 0.12% of Zymeworks worth $1,008,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZYME. Perceptive Advisors LLC increased its stake in shares of Zymeworks by 55.2% during the second quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock worth $14,192,000 after purchasing an additional 592,904 shares during the period. Rubric Capital Management LP grew its position in Zymeworks by 12.7% during the second quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company’s stock worth $33,336,000 after buying an additional 441,947 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Zymeworks by 127.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock worth $6,090,000 after acquiring an additional 401,068 shares during the period. Assenagon Asset Management S.A. bought a new position in Zymeworks during the 3rd quarter worth $4,156,000. Finally, Point72 Asset Management L.P. bought a new position in Zymeworks during the 2nd quarter worth $1,683,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Trading Up 0.1 %

ZYME opened at $14.51 on Tuesday. The company’s 50 day moving average is $14.27 and its 200-day moving average is $12.07. The company has a market cap of $999.42 million, a P/E ratio of -9.67 and a beta of 1.12. Zymeworks Inc. has a 1-year low of $7.97 and a 1-year high of $17.70.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. During the same quarter last year, the business earned ($0.41) EPS. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. On average, equities analysts forecast that Zymeworks Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. HC Wainwright reiterated a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Citigroup increased their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Stifel Nicolaus increased their price objective on shares of Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Finally, Leerink Partners upgraded shares of Zymeworks from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $10.00 to $25.00 in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and a consensus price target of $19.17.

Insider Activity

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock in a transaction that occurred on Thursday, December 26th. The stock was acquired at an average price of $14.38 per share, with a total value of $240,030.96. Following the transaction, the director now owns 14,720,931 shares in the company, valued at $211,686,987.78. This trade represents a 0.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.92% of the stock is currently owned by company insiders.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.